The effects of a new alpha- and beta-adrenoceptor antagonist (AH5158) upon the general and coronary haemodynamics of intact dogs.
AH5158, a salicylamide derivative, said to be a blocker of alpha- and beta-adrenoceptors, has been studied in intact anaesthetized dogs. At a dose of 2.5 mg/kg intravenously, the drug increased cardiac output and caused a late fall in mean systemic and pulmonary arterial pressure. Coronary sinus flow increased, as did cardiac oxygen extraction. External cardiac efficiency decreased. Blood glucose and non-esterified fatty acid values increased, but cardiac extraction of these did not change.
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002082:Butylamines / Q000008:administration & dosage / Q000494:pharmacology; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects; D003864:Depression, Chemical; D004285:Dogs; D004983:Ethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D010100:Oxygen / Q000097:blood; D012457:Salicylamides / Q000008:administration & dosage / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D002082:Butylamines; D004983:Ethanolamines; D012457:Salicylamides; D014665:Vasodilator Agents; D002245:Carbon Dioxide; D010100:Oxygen